甲基化DNA标志物用于卵巢癌血浆检测:发现、验证与临床可行性
研究通过对卵巢癌组织、良性输卵管上皮和健康女性血沉棕黄层进行简并代表性亚硫酸氢盐测序,发现33个甲基化DNA标志物,并在91例卵巢癌患者和91例无癌女性的血浆中验证11个标志物组合,交叉验证显示特异性96%、敏感性79%、AUC 0.91,5例I/II期高级别浆液性癌均被正确识别,作者认为需开展更大规模血浆标志物研究。
要点
- 11个甲基化DNA标志物组合在血浆中区分卵巢癌与对照的交叉验证AUC为0.91(95%CI 0.86-0.96)。
- 该组合特异性96%(95%CI 89-99%),敏感性79%(95%CI 69-87%)。
- 5例I/II期高级别浆液性卵巢癌均被正确识别。
核心结论
- 全甲基化组测序、严格筛选标准和生物学验证产生的卵巢癌候选甲基化DNA标志物在血浆中表现出高敏感性和特异性。
- 作者认为需开展更大规模的血浆卵巢癌甲基化DNA标志物研究,包括检测诊断前标本。
研究设计与样本
- 研究对卵巢癌冷冻组织、良性输卵管上皮和無癌女性血沉棕黄层DNA进行简并代表性亚硫酸氢盐测序以发现卵巢癌甲基化DNA标志物。
- 候选标志物基于受试者工作特征曲线判别、甲基化倍数变化和对照中低背景甲基化进行选择。
- 使用甲基化特异性PCR对独立卵巢癌和输卵管上皮福尔马林固定石蜡包埋组织DNA进行盲法生物学验证。
- 在91例新诊断卵巢癌女性(73例(80%)为高级别浆液性癌)和91例无癌女性的治疗前血浆中使用靶向富集长探针定量扩增信号(TELQAS)检测标志物。
- 采用随机森林建模分析生成疾病预测概率,结果进行500倍计算机交叉验证。
主要发现
- 33个甲基化DNA标志物在所有卵巢癌亚型与输卵管上皮相比显示显著甲基化倍数变化(10至>1000)。
- 11个甲基化DNA标志物(GPRIN1、CDO1、SRC、SIM2、AGRN、FAIM2、CELF2、RIPPLY3、GYPC、CAPN2、BCAT1)在91例卵巢癌女性(73例(80%)为高级别浆液性癌)和91例无癌女性血浆中检测,交叉验证的11标志物组合高度区分卵巢癌与对照,特异性96%(95%CI 89-99%),敏感性79%(95%CI 69-87%),AUC 0.91(95%CI 0.86-0.96)。
- 纳入的5例I/II期高级别浆液性卵巢癌均被正确识别。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 作者认为需开展更大规模的血浆卵巢癌甲基化DNA标志物研究,包括检测诊断前标本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Aberrant DNA methylation is an early event in carcinogenesis which could be leveraged to detect ovarian cancer (OC) in plasma. METHODS: DNA from frozen OC tissues, benign fallopian tube epithelium (FTE), and buffy coats from cancer-free women underwent reduced representation bisulfite sequencing (RRBS) to identify OC MDMs. Candidate MDM selection was based on receiver operating characteristic (ROC) discrimination, methylation fold change, and low background methylation among controls. Blinded biological validation was performed using methylated specific PCR on DNA extracted from independent OC and FTE FFPE tissues. MDMs were tested using Target Enrichment Long-probe Quantitative Amplified Signal (TELQAS) assays in pre-treatment plasma from women newly diagnosed with OC and population-sampled healthy women. A random forest modeling analysis was performed to generate predictive probability of disease; results were 500-fold in silico cross-validated. RESULTS: Thirty-three MDMs showed marked methylation fold changes (10 to >1000) across all OC subtypes vs FTE. Eleven MDMs (GPRIN1, CDO1, SRC, SIM2, AGRN, FAIM2, CELF2, RIPPLY3, GYPC, CAPN2, BCAT1) were tested on plasma from 91 women with OC (73 (80%) high-grade serous (HGS)) and 91 without OC; the cross-validated 11-MDM panel highly discriminated OC from controls (96% (95% CI, 89-99%) specificity; 79% (69-87%) sensitivity, and AUC 0.91 (0.86-0.96)). Among the 5 stage I/II HGS OCs included, all were correctly identified. CONCLUSIONS: Whole methylome sequencing, stringent filtering criteria, and biological validation yielded candidate MDMs for OC that performed with high sensitivity and specificity in plasma. Larger plasma-based OC MDM studies, including testing of pre-diagnostic specimens, are warranted.
引用
- Marinelli LM, Kisiel JB, Slettedahl SW, et al. Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility. Gynecol Oncol. 2022. PMID: 35370009. doi:10.1016/j.ygyno.2022.03.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。